产品
编 号：F754605
分子式：C32H33F4N5O3
分子量：611.63
分子式：C32H33F4N5O3
分子量：611.63
产品类型
规格
价格
是否有货
结构图
CAS No: 2684258-54-4
产品详情
生物活性：
RET-IN-13 (compound 1), a quinoline compound, is a potent RET inhibitor with IC50s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research.
体内研究：
RET-IN-13 (compound 1; 0.5 mpk; iv) has a T1/2 of 6.93 hours, a CL of 2.68 mL/min·kg, and a Vdss of 1.52 L/kg for male mice.RET-IN-13 (2.5 mpk; po) has a T1/2 of 5.16 hours, Cmax of 0.958 μM and an AUC of 12477 μM·hr for male mice.
体外研究：
RET-IN-13 has low inhibition on CYP1A2 (IC50>50 μM), CYP2C9 (IC50=12.5 μM), CYP2C19 (IC50=16.9 μM), CYP2D6 (IC50=18.8 μM) and CYP3A4 (IC50>50 μM).
RET-IN-13 (compound 1), a quinoline compound, is a potent RET inhibitor with IC50s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research.
体内研究：
RET-IN-13 (compound 1; 0.5 mpk; iv) has a T1/2 of 6.93 hours, a CL of 2.68 mL/min·kg, and a Vdss of 1.52 L/kg for male mice.RET-IN-13 (2.5 mpk; po) has a T1/2 of 5.16 hours, Cmax of 0.958 μM and an AUC of 12477 μM·hr for male mice.
体外研究：
RET-IN-13 has low inhibition on CYP1A2 (IC50>50 μM), CYP2C9 (IC50=12.5 μM), CYP2C19 (IC50=16.9 μM), CYP2D6 (IC50=18.8 μM) and CYP3A4 (IC50>50 μM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备